DT-7012 nominated based on its unique ability, as a monotherapy, to cure cancer in preclinical studies Phase I study with DT-7012 expected to start by mid-2025 Follows recent candidate nomination… Read More
In Addition, Board has Accepted Recent Director Resignations and has Initiated a Search for New Directors EDMONTON, AB — (BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the… Read More
SAN DIEGO, CA — /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company… Read More
MISSISSAUGA, ON — GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives… Read More
VANCOUVER, BC — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF)(“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced… Read More
